AGÕæÈ˹ٷ½

STOCK TITAN

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
X4 Pharmaceuticals (XFOR) has announced the issuance of inducement awards to new employees under its 2019 Inducement Plan. The awards consist of stock options to purchase 5,545 shares of common stock, granted on May 30, 2025. The options have a ten-year term with an exercise price of $3.40 per share, matching X4's closing stock price on the grant date. The vesting schedule spans four years, with 25% vesting after the first year and the remainder vesting monthly over the following 36 months, contingent on continued employment. These grants, approved by X4's Compensation Committee, were made in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement for new employee recruitment.
X4 Pharmaceuticals (XFOR) ha annunciato l'assegnazione di premi di incentivo a nuovi dipendenti nell'ambito del suo Piano di Incentivazione 2019. I premi consistono in opzioni su azioni per l'acquisto di 5.545 azioni ordinarie, concesse il 30 maggio 2025. Le opzioni hanno una durata di dieci anni e un prezzo di esercizio di 3,40 dollari per azione, corrispondente al prezzo di chiusura delle azioni X4 alla data di concessione. Il piano di maturazione prevede un periodo di quattro anni, con il 25% delle opzioni che maturano dopo il primo anno e il restante che matura mensilmente nei successivi 36 mesi, subordinato alla continuazione dell'impiego. Queste concessioni, approvate dal Comitato per la Retribuzione di X4, sono state effettuate in conformità con la Regola 5635(c)(4) del Nasdaq come incentivo per l'assunzione di nuovi dipendenti.
X4 Pharmaceuticals (XFOR) ha anunciado la emisión de premios por inducción a nuevos empleados bajo su Plan de Inducción 2019. Los premios consisten en opciones sobre acciones para comprar 5,545 acciones comunes, otorgadas el 30 de mayo de 2025. Las opciones tienen un plazo de diez años con un precio de ejercicio de 3,40 dólares por acción, igualando el precio de cierre de X4 en la fecha de concesión. El calendario de adquisición se extiende por cuatro años, con un 25% que se adquiere después del primer año y el resto que se adquiere mensualmente durante los siguientes 36 meses, condicionado a la continuidad laboral. Estas concesiones, aprobadas por el Comité de Compensación de X4, se realizaron conforme a la Regla 5635(c)(4) de Nasdaq como incentivo para la contratación de nuevos empleados.
X4 Pharmaceuticals(XFOR)ëŠ� 2019ë…� ìœ ì¸ ê³„íšì—� ë”°ë¼ ì‹ ê·œ ì§ì›ì—게 ìœ ì¸ ìƒì—¬ë¥� 발행했다ê³� 발표했습니다. ìƒì—¬ëŠ� 2025ë…� 5ì›� 30ì¼ì— ë¶€ì—¬ëœ ë³´í†µì£� 5,545주를 매수í•� ìˆ� 있는 스톡 옵션으로 구성ë©ë‹ˆë‹�. 옵션ì� 유효 ê¸°ê°„ì€ 10ë…„ì´ë©�, 행사 ê°€ê²©ì€ ë¶€ì—¬ì¼ì� X4 종가ì� 주당 3.40달러입니ë‹�. 베스íŒ� ì¼ì •ì€ 4ë…„ì— ê±¸ì³ ì§„í–‰ë˜ë©°, ì²� í•´ê°€ ì§€ë‚� í›� 25%ê°€ 베스팅ë˜ê³� 나머지ëŠ� 향후 36개월 ë™ì•ˆ 매월 베스팅ë˜ë©� ê³„ì† ê³ ìš© ì¡°ê±´ì� 붙습니다. ì� ìƒì—¬ëŠ� X4 ë³´ìƒ ìœ„ì›íšŒì—ì„� 승ì¸í–ˆìœ¼ë©�, ì‹ ê·œ ì§ì› 채용 유ì¸ì� 위한 나스ë‹� ìƒìž¥ 규칙 5635(c)(4)ì—� ë”°ë¼ ì´ë£¨ì–´ì¡ŒìŠµë‹ˆë‹�.
X4 Pharmaceuticals (XFOR) a annoncé l'attribution de primes d'incitation à de nouveaux employés dans le cadre de son Plan d'Incitation 2019. Ces primes consistent en des options d'achat de 5 545 actions ordinaires, accordées le 30 mai 2025. Les options ont une durée de dix ans avec un prix d'exercice de 3,40 $ par action, correspondant au cours de clôture de X4 à la date d'attribution. Le calendrier d'acquisition s'étale sur quatre ans, avec 25 % acquis après la première année et le reste acquis mensuellement sur les 36 mois suivants, sous réserve de la poursuite de l'emploi. Ces attributions, approuvées par le Comité de Rémunération de X4, ont été effectuées conformément à la règle 5635(c)(4) du Nasdaq en tant qu'incitation au recrutement de nouveaux employés.
X4 Pharmaceuticals (XFOR) hat die Vergabe von Anreizprämien an neue Mitarbeiter im Rahmen seines Inducement-Plans von 2019 angekündigt. Die Prämien bestehen aus Aktienoptionen zum Kauf von 5.545 Stammaktien, die am 30. Mai 2025 gewährt wurden. Die Optionen haben eine Laufzeit von zehn Jahren und einen Ausübungspreis von 3,40 USD pro Aktie, was dem Schlusskurs von X4 am Tag der Gewährung entspricht. Der Vesting-Zeitplan erstreckt sich über vier Jahre, wobei 25 % nach dem ersten Jahr und der Rest monatlich über die folgenden 36 Monate vesten, vorausgesetzt die Beschäftigung wird fortgesetzt. Diese Zuteilungen wurden vom Vergütungsausschuss von X4 genehmigt und gemäß der Nasdaq-Listing-Regel 5635(c)(4) als Anreiz für die Rekrutierung neuer Mitarbeiter vorgenommen.
Positive
  • None.
Negative
  • None.

BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on May 30, 2025, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the �2019 Inducement Plan�). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 5,545 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.

The options have a ten-year term and an exercise price of $3.40 per share, which is equal to the closing price of X4’s common stock on May 30, 2025. Each option will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employee’s continued employment with X4 on such vesting dates. The options are subject to the terms and conditions of the 2019 Inducement Plan and the terms and conditions of an award agreement covering the grant.

About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging expertise in CXCR4 and immune system biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is currently being marketed in the U.S. as in its first indication. The company is also evaluating additional uses of mavorixafor and is conducting a global, pivotal Phase 3 clinical trial () in people with certain chronic neutropenic disorders. X4 is headquartered in Boston, Massachusetts. For more information, please visit .

Investor Contact:
Daniel Ferry
Managing Director, LifeSci Advisors

(617) 430-7576


FAQ

What are the details of X4 Pharmaceuticals (XFOR) inducement grants announced in June 2025?

X4 Pharmaceuticals issued stock options for 5,545 shares with an exercise price of $3.40 per share, vesting over four years with 25% after the first year and the remainder monthly over 36 months.

What is the vesting schedule for XFOR's May 2025 inducement stock options?

The options vest over 4 years, with 25% vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to continued employment.

What is the exercise price for X4 Pharmaceuticals' May 2025 inducement stock options?

The exercise price is $3.40 per share, equal to X4's closing stock price on May 30, 2025.

What is the purpose of X4 Pharmaceuticals' 2019 Inducement Plan?

The 2019 Inducement Plan is exclusively used for granting equity awards to individuals who were not previously X4 employees as an inducement for employment.
X4 Pharmaceuticals Inc

NASDAQ:XFOR

XFOR Rankings

XFOR Latest News

XFOR Latest SEC Filings

XFOR Stock Data

10.70M
5.33M
2.49%
57.89%
5.44%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
BOSTON